BeiGene (HKG:6160, SHA:688235) granted options to three grantees to subscribe for an aggregate of 3,754 American Depositary Shares (ADSs) on Aug. 30, a Thursday bourse filing said.
The options, which were granted under a 2016 share option and incentive plan, are exercisable at $198.37 per ADS for a period of 10 years.
The company, on the same day, granted a total of 66,829 restricted share unit (RSUs) to 179 Grantees under the same scheme. The RSUs represent 868,777 underlying shares, representing around 0.06% of the company's total issued share capital.
Following the grant of the options and RSUs, the drug company will have 81,050,878 underlying shares available for future grants under the award plan.
Hong Kong-listed shares of the company closed nearly 3% higher on Thursday.
Price (HKD): $115.10, Change: $+2.9, Percent Change: +2.58%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。